Wednesday, January 14

Healthcare

Scinai Immunotherapeutics regains compliance with Nasdaq listing rule

08/30/20241 Min Read

compliance Immunotherapeutics listing Nasdaq regains rule Scinai

Previous ArticleVeeva spikes on above-consensus earnings guidance

Next Article Merck stops two more cancer trials over poor results